Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 215-223

  Li, Ni ^a,b   Peng, Li Hua ^a   Chen, Xi ^a   Zhang, Tian Yuan ^a   Shao, Guo Feng ^b   Liang, Wen Quan ^a   Gao, Jian Qing ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b NINGBO UNIVERSITY   (China)

^c The Novel Transdermal Research Center of Jiangsu Province   (China)

Author keywords

Antigen; Chitosan nanoparticle; Langerhans cell; Lymph nodes; Transcutaneous immunization

Indexed keywords

ANTIGEN PRESENTING CELLS; CHITOSAN NANOPARTICLES; FLUORESCEIN ISOTHIOCYANATE; LANGERHANS CELLS; LOW MOLECULAR WEIGHT; LYMPH NODE; TRANSCUTANEOUS IMMUNIZATIONS; TRIPOLYPHOSPHATES;

BODY FLUIDS; CELLS; CHITOSAN; CYTOLOGY; IMMUNIZATION; NANOPARTICLES;

ANTIGENS;

CHITOSAN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN GP 100; IMIQUIMOD; IMMUNOGLOBULIN G; NANOCARRIER; OVALBUMIN; TRIPOLYPHOSPHATE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; DRUG STABILITY; DRUG UPTAKE; FEMALE; IMMUNIZATION; LANGERHANS CELL; LYMPH NODE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; STRATUM CORNEUM; THERAPY EFFECT;

MUS;

ANTIGEN; CHITOSAN NANOPARTICLE; LANGERHANS CELL; LYMPH NODES; TRANSCUTANEOUS IMMUNIZATION;

ANIMALS; ANTIGENS; CELL MOVEMENT; DRUG CARRIERS; HUMANS; IMMUNIZATION; LANGERHANS CELLS; LYMPH NODES; MICE; NANOPARTICLES;

EID: 84890998661     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.06.007     Document Type: Article

References (50)

1. Cui Z., Dierling A., Foldvari M. Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv 2006, 3:29-35.
2. Peachman K.K., Rao M., Alving C.R. Immunization with DNA through the skin. Methods 2003, 31:232-242.
3. Li N., Peng L.H., Chen X., Nakagawa S., Gao J.Q. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo. Int J Nanomedicine 2011, 6:3241-3250.
4. Glenn G.M., Kenney R.T., Ellingsworth L.R., Frech S.A., Hammond S.A., Zoeteweij J.P. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003, 2:253-267.
5. Hammond S.A., Guebre-Xabier M., Yu J., Glenn G.M. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 2001, 18:503-526.
6. Zhao Q.Q., Chen J.L., Lv T.F., He C.X., Tang G.P., Liang W.Q., et al. N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex. Biol Pharm Bull 2009, 32:706-710.
7. Gao J.Q., Zhao Q.Q., Lv T.F., Shuai W.P., Zhou J., Tang G.P., et al. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int J Pharm 2010, 387:286-294.
8. Zheng C.H., Gao J.Q., Zhang Y.P., Liang W.Q. A protein delivery system: biodegradable alginate-chitosan-poly(lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun 2004, 323:1321-1327.
9. Li N., Hu Y.L., He C.X., Hu C.J., Zhou J., Tang G.P., et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. J Pharm Pharmacol 2010, 62:139-144.
10. Zheng X., Huang Y., Zheng C., Dong S., Liang W. Alginate-chitosan-PLGA composite microspheres enabling single-shot hepatitis B vaccination. AAPS J 2010, 12:519-524.
11. Duncan G., Jess T.J., Mohamed F., Price N.C., Kelly S.M., van der Walle C.F. The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. J Control Release 2005, 110:34-48.
12. Fonte P., Andrade F., Araujo F., Andrade C., Neves J., Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol 2012, 508:295-314.
13. Yoshikawa T., Okada N., Tsujino M., Gao J.Q., Hayashi A., Tsutsumi Y., et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol Pharm Bull 2006, 29:100-104.
14. Sugita T., Yoshikawa T., Gao J.Q., Shimokawa M., Oda A., Niwa T., et al. Fusogenic liposome can be used as an effective vaccine carrier for peptide vaccination to induce cytotoxic T lymphocyte (CTL) response. Biol Pharm Bull 2005, 28:192-193.
15. Yoshikawa T., Imazu S., Gao J.Q., Hayashi K., Tsuda Y., Okada N., et al. Non-methylated CpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice. Biol Pharm Bull 2006, 29:105-109.
16. Zamboni W.C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11:8230-8234.
17. Fredriksen B.N., Grip J. PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.). Vaccine 2012, 30:656-667.
18. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 2011, 108:E989-E997.
19. Jabbal-Gill I., Watts P., Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv 2012, 9:1051-1067.
20. Hansen S., Lehr C.M. Nanoparticles for transcutaneous vaccination. Microb Biotechnol 2012, 5:156-167.
21. Yoshikawa T., Okada N., Oda A., Matsuo K., Kayamuro H., Ishii Y., et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 2008, 26:1303-1313.
22. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
23. Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C.D., Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010, 385:187-193.
24. Hasanovic A., Zehl M., Reznicek G., Valenta C. Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability. J Pharm Pharmacol 2009, 61:1609-1616.
25. Huang Y.Z., Gao J.Q., Liang W.Q., Nakagawa S. Preparation and characterization of liposomes encapsulating chitosan nanoparticles. Biol Pharm Bull 2005, 28:387-390.
26. Takagi K., Teshima R., Okunuki H., Sawada J. Comparative study of in vitro digestibility of food proteins and effect of preheating on the digestion. Biol Pharm Bull 2003, 26:969-973.
27. Williamson M.R., Chang H.I., Coombes A.G. Gravity spun polycaprolactone fibres: controlling release of a hydrophilic macromolecule (ovalbumin) and a lipophilic drug (progesterone). Biomaterials 2004, 25:5053-5060.
28. Wagner S.N., Wagner C., Luhrs P., Weimann T.K., Kutil R., Goos M., et al. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol 2000, 115:1082-1087.
29. Rakhmilevich A.L., Imboden M., Hao Z., Macklin M.D., Roberts T., Wright K.M., et al. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 2001, 7:952-961.
30. Nawrath M., Pavlovic J., Dummet R., Schultz J., Strack B., Heinrich J., et al. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17. Leukemia 1999, 13(Suppl. 1):S48-S51.
31. Miltenyi S., Muller W., Weichel W., Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990, 11:231-238.
32. Lee P.W., Hsu S.H., Tsai J.S., Chen F.R., Huang P.J., Ke C.J., et al. Multifunctional core-shell polymeric nanoparticles for transdermal DNA delivery and epidermal Langerhans cells tracking. Biomaterials 2010, 31:2425-2434.
33. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., Schaefer H., et al. 40nm, but not 750 or 1,500nm, nanoparticles enter epidermal CD1a+cells after transcutaneous application on human skin. J Invest Dermatol 2006, 126:1316-1322.
34. Blume-Peytavi U., Massoudy L., Patzelt A., Lademann J., Dietz E., Rasulev U., et al. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur J Pharm Biopharm 2010, 76:450-453.
35. Sparber F., Tripp C.H., Hermann M., Romani N., Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology 2010, 215:770-779.
36. Caux C., Dubois B. Antigen uptake by dendritic cells. Methods Mol Med 2001, 64:369-376.
37. Combadiere B., Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin 2011, 7:811-827.
38. Liard C., Munier S., Joulin-Giet A., Bonduelle O., Hadam S., Duffy D., et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 2012, 132:615-625.
39. Hammond S.A., Walwender D., Alving C.R., Glenn G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 2001, 19:2701-2707.
40. Jarmila V., Vavrikova E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-a review. Curr Pharm Des 2011, 17:3596-3607.
41. Nagpal K., Singh S.K., Mishra D.N. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull(Tokyo) 2010, 58:1423-1430.
42. Klippstein R., Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 2010, 6:523-529.
43. Lamalle-Bernard D., Munier S., Compagnon C., Charles M.H., Kalyanaraman V.S., Delair T., et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J Control Release 2006, 115:57-67.
44. Puri N., Sinko P.J. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J Control Release 2000, 69:69-80.
45. Mahe B., Vogt A., Liard C., Duffy D., Abadie V., Bonduelle O., et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009, 129:1156-1164.
46. Bal S.M., Slutter B., Verheul R., Bouwstra J.A., Jiskoot W. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 2012, 45:475-481.
47. Wang W.X., Gao J.Q., Liang W.Q. Chitosan-coated liposomes for intracellular oligonucleotides delivery: characteristics and cell uptake behavior. Drug Deliv 2011, 18:208-214.
48. Papakostas D., Rancan F., Sterry W., Blume-Peytavi U., Vogt A. Nanoparticles in dermatology. Arch Dermatol Res 2011, 303:533-550.
49. Liard C., Munier S., Arias M., Joulin-Giet A., Bonduelle O., Duffy D., et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 2011, 29:6379-6391.
50. Li N., Peng L.H., Chen X., Nakagawa S., Gao J.Q. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 2011, 29:6179-6190.